Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer

Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer

Yanmei Wu,1 Yu Zhang,2 Hao Pi,1 Yuan Sheng1 1Department of Breast and Thyroid Surgery, Changhai Hospital, Navy Medical University, Shanghai 200433, People’s Republic of China; 2Medical Affairs, Pfizer Biopharmaceutical Group, Shanghai 200041, People’s Republic of ChinaCorresponde...

Full description

Bibliographic Details
Main Authors:	Wu Y, Zhang Y, Pi H, Sheng Y
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-05-01
Series:	Cancer Management and Research
Subjects:	cdk4/6 inhibitor breast cancer mechanism clinical efficacy resistance
Online Access:	https://www.dovepress.com/current-therapeutic-progress-of-cdk46-inhibitors-in-breast-cancer-peer-reviewed-article-CMAR

Similar Items

Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
by: Navid Sobhani, et al.
Published: (2021-02-01)

CDK4/6 inhibitors in advanced breast cancer, what is beyond?
by: Amrallah A. Mohammed, et al.
Published: (2019-07-01)

The Pharmacological Profile of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors: Clinical Management of Toxicity and Drug Interactions Related to CDK 4/6 Inhibitor-based Treatment in Advanced/Metastatic Breast Cancer
by: Vasiliki Tzelepi C., et al.
Published: (2020-04-01)

CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
by: Debora de Melo Gagliato, et al.
Published: (2020-09-01)

LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer
by: Xi Jin, et al.
Published: (2020-05-01)

Recent advances of highly selective CDK4/6 inhibitors in breast cancer
by: Hanxiao Xu, et al.
Published: (2017-04-01)

CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience
by: Angeliki Andrikopoulou, et al.
Published: (2021-06-01)

Role of CDK4/CDK6 inhibitors: Ribociclib, Palbocilcib and Abemacilcib in treatment of metastatic breast cancer
by: Ghobadpour, Nazanin
Published: (2021)

Progress of CDK4/6 inhibitors in the treatment of malignant tumors
by: Bin Fu, et al.
Published: (2019-11-01)

Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
by: Angeliki Andrikopoulou, et al.
Published: (2021-01-01)

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
by: Mattia Garutti, et al.
Published: (2021-05-01)

CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
by: Yilan Yang, et al.
Published: (2020-09-01)

CDK4/6 Inhibitors-based Combinational Therapy for Human Cancers
by: ZHANG Baihong, et al.
Published: (2019-01-01)

SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors
by: Flora Zagouri, et al.
Published: (2021-12-01)

CDK4/6 inhibitors in the treatment of metastatic breast cancer. Choosing optimal therapy for estrogen-receptor-positive HER2-negative metastatic breast cancer: analysis of doctors’ preferences (“Prometheus”) in Russia – first results of the survey
by: E. V. Artamonova, et al.
Published: (2021-01-01)

MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment
by: Angeliki Andrikopoulou, et al.
Published: (2021-08-01)

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
by: Xiuzhi Zhu, et al.
Published: (2021-04-01)

Research Progress of CDK4/6 Inhibitors in Non-small Cell Lung Cancer
by: Qiong QIN, et al.
Published: (2020-03-01)

Ki67 and PR in Patients Treated with CDK4/6 Inhibitors: A Real-World Experience
by: Michela Palleschi, et al.
Published: (2020-08-01)

Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
by: Zhen Li, et al.
Published: (2020-11-01)

Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors
by: Michela Piezzo, et al.
Published: (2020-09-01)

Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
by: Mridula A. George, et al.
Published: (2021-07-01)

A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy
by: Albert Grinshpun, et al.
Published: (2020-06-01)

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer
by: Ilenia Migliaccio, et al.
Published: (2021-05-01)

CDK 4/6 inhibitors combined with radiotherapy: A review of literature
by: Claire Bosacki, et al.
Published: (2021-01-01)

Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
by: Michela Piezzo, et al.
Published: (2020-09-01)

Advances in Therapy for Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer Patients Who Have Experienced Progression After Treatment with CDK4/6 Inhibitors
by: Li C, et al.
Published: (2021-05-01)

Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience
by: Irina V. Kolyadina, et al.
Published: (2020-07-01)

Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial
by: A. van Ommen-Nijhof, et al.
Published: (2018-11-01)

Personalized Medicine and Biomarker Discovery to Targeted Therapies in Breast Cancer : Focus on CDK4/6 Inhibitors
by: Arnedos Ballester, Monica
Published: (2019)

The place of CDK4/6 inhibitors in real clinical practice for patients with hormone-positive HER2-negative advanced breast cancer: opinion of Moscow’s oncologists
by: L. G. Zhukova, et al.
Published: (2020-06-01)

Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
by: Kamal Pandey, et al.
Published: (2020-11-01)

Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors
by: Lucrezia Raimondi, et al.
Published: (2021-04-01)

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
by: Corona SP, et al.
Published: (2018-02-01)

Adjuvant CDK4/6 inhibitors combined with endocrine therapy in HR-positive, HER2-negative early breast cancer: A meta-analysis of randomized clinical trials
by: Hong-Fei Gao, et al.
Published: (2021-10-01)

Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer
by: Kase AM, et al.
Published: (2020-10-01)

MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
by: Neil Portman, et al.
Published: (2020-08-01)

Oncogenic PAX6 elicits CDK4/6 inhibitor resistance by epigenetically inactivating the LATS2‐Hippo signaling pathway
by: Yi Zhang, et al.
Published: (2021-08-01)

Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review
by: Anna Maria Militello, et al.
Published: (2019-08-01)

CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer: Potential Molecular Mechanisms, Clinical Implications and Future Perspectives
by: Michela Roberto, et al.
Published: (2021-01-01)